Therefore, reduced IL-33 expression in metastatic mouse carcinomas simultaneously decreases both the MHC-I expression and the functional activities of ILC2s and provides a previously undescribed mechanism of immune escape for tumour cells. The gene discussed is IL33; the disease is neoplasm.